Some Investors Depressed About Biovail’s Buyout Of U.S. Wellbutrin Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
Dividend cut also hurts shares, as the company continues its move toward the neurology space.
You may also be interested in...
Wellbutrin XL Generic Needs Longer Study To Assess Switch Issues, Biovail Asserts
Bioequivalencey isn't the issue, Biovail says in response to proposed Teva study, arguing a much larger and differently designed trial should be conducted to investigate clinical differences between the generic and brand.
Wellbutrin XL Generic Needs Longer Study To Assess Switch Issues, Biovail Asserts
Bioequivalencey isn't the issue, Biovail says in response to proposed Teva study, arguing a much larger and differently designed trial should be conducted to investigate clinical differences between the generic and brand.
Biovail Walks The Walk: More CNS Licensing, Acquisitions Planned For 2010
Biovail is putting its money where its mouth is. The Toronto-based specialty pharma announced plans early in 2008 to turn itself into a specialty central nervous system company, and - after five deals in 18 months -Biovail execs are more excited than ever about the opportunities open to them